IdentifiHR predicts homologous recombination deficiency in high-grade serous ovarian carcinoma using gene expression
Open Access
- 14 January 2026
- journal article
- research article
- Published by Springer Nature in Communications Medicine
- Vol. 6 (1)
Abstract
Background: Approximately half of all high-grade serous ovarian carcinomas (HGSCs) have a therapeutically targetable defect in homologous recombination (HR) DNA repair. While there are genomic and transcriptomic methods, developed for other cancers, to identify HR deficient (HRD) samples, there are no gene expression-based tools to predict HR status in HGSC specifically. We have built a HGSC-specific model to predict HR status using gene expression. Methods: We separated The Cancer Genome Atlas (TCGA) cohort of HGSCs into training ( n = 288) and testing ( n = 73) sets and labelled each case as HRD or HR proficient (HRP) based on the clinical standard for classification. Using the training set, we performed differential gene expression analysis between HRD and HRP cases. The 2604 significantly differentially expressed genes were used to train a penalised logistic regression model. Results: IdentifiHR uses the expression of 209 genes to predict HR status in HGSC. These genes preserve the genomic damage signal, capturing known regions of HR-specific copy number alteration which impact gene expression. IdentifiHR is 85% accurate in the TCGA test set and 86% accurate in an independent cohort of 99 samples, taken from primary tumours, ascites and normal fallopian tubes. Further, IdentifiHR is 84% accurate in pseudobulked single-cell HGSC sequencing from 37 patients and outperforms existing expression-based methods to predict HR status, being BRCAness, MutliscaleHRD and expHRD. Conclusions: IdentifiHR is an accurate model to predict HR status in HGSC. It is available as an open source R package, empowering researchers to robustly classify HR status when only transcriptomic sequencing data is available.Keywords
Funding Information
- Department of Health | National Health and Medical Research Council (GNT2016547)
- Department of Health | National Health and Medical Research Council (GNT2009840)
This publication has 54 references indexed in Scilit:
- HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinomaGynecologic Oncology, 2023
- ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancerAnnals of Oncology, 2020
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trialThe Lancet Oncology, 2019
- Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome AtlasCell Reports, 2018
- ascatNgs: Identifying Somatically Acquired Copy‐Number Alterations from Whole‐Genome Sequencing DataCurrent Protocols in Bioinformatics, 2016
- Detection of somatic BRCA1/2 mutations in ovarian cancer – next‐generation sequencing analysis of 100 casesCancer Medicine, 2016
- Clinical implications of the intrinsic molecular subtypes of breast cancerThe Breast, 2015
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancerBritish Journal of Cancer, 2012
- PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancerBreast Cancer Research and Treatment, 2012
- Integrated genomic analyses of ovarian carcinomaNature, 2011